Anti-inflammatory and immunomodulatory strategies in VAP - Lessons from adult Intensive Care
|
|
- Linda Horn
- 5 years ago
- Views:
Transcription
1 Anti-inflammatory and immunomodulatory strategies in VAP - Lessons from adult Intensive Care Charles Feldman Professor of Pulmonology Charlotte Maxeke Johannesburg Academic Hospital University of the Witwatersrand
2 Disclosures Acted on the advisory board and/or received honoraria for lectures from pharmaceutical companies manufacturing and/or marketing macrolide antibiotics (Abbott, Aspen-GSK, Pfizer, Sandoz)
3 Adjunctive Therapies in VAP Macrolides Corticosteroids Statins Nebulised antibiotics Other
4 Macrolides Assessed for eligibility (n=218) PLACEBO Allocated to intervention (n=100) Received allocated intervention (n=100) Enrolment Randomisation Allocation Excluded (n=18) Not meeting inclusion criteria (n=19) Refused to participate (n=0) Other reasons (n=0) CLARITHROMYCIN Clarithromycin 1g IVI for 3 days Allocated to intervention (n=100) Received allocated intervention (n=100) Lost to follow-up (n=0) Discontinued intervention (n=0) Follow-up Lost to follow-up (n=0) Discontinued intervention (n=1) Reason for discontinuation: SAE: bronchospasm Analysed (n=100) Excluded from analysis (n=0) Analysis Analysed (n=100) Excluded from analysis (n=0) Giamarellos-Bourboulis EJ et al. Clin Infect Dis 2008;46:
5 Cumulative Incidence of Resolution of VAP 80% % of resolved cases 60% 40% 20% Clarithromycin Placebo 0% Time (days) Giamarellos-Bourboulis EJ et al. Clin Infect Dis 2008;46:
6 Cumulative Time to Weaning from MV 80% % of de-intubated patients 60% 40% 20% Clarithromycin Placebo 0% Time (days) Giamarellos-Bourboulis EJ et al. Clin Infect Dis 2008;46:
7 Cumulative Time to Death from Sepsis 80% % of dead patients 80% 60% 40% Placebo Clarithromycin 20% 0% Time (days) Giamarellos-Bourboulis EJ et al. Clin Infect Dis 2008;46:
8 Review of Macrolides - Key Points Macrolides inhibit production of proinflammatory cytokines in animal models of acute lung infection Macrolides inhibit quorum sensing of P. aeruginosa that allows creation of biofilms and firm adherence to the airways Retrospective data suggest that addition of a macrolide has survival benefit in severe CAP One randomised clinical study in patients with VAP proved that administration of intravenous clarithromycin was accompanied by earlier resolution of pneumonia Mouktaroudi M et al. Curr Opin Infect Dis 2012; 25:
9 Sites of Action that Make Macrolides Promising Adjunctive Options for Nosocomial Infections mucin IL-1β, IL-6, IL-8 Airway epithelium Alveolar space Macrophage TNFα, IL-6 influx by circulating macrophages Macrolides P. aeruginosa Circulating mononuclear cells lasl+rhla expression epithelial junctions lymphocyte apoptosis TNFα Mouktaroudi M et al. Curr Opin Infect Dis 2012; 25:
10 Main Effects of Treatment with Clarithromycin Serum ShMODS IL-10.TNFα Monocytes Non-ShMODS mcd86 TNFα Non-ShMODS TNFα Non-ShMODS mtrem-1 TNFα ShMODS mtrem-1 ShMODS Apoptosis mcd86 TNFα IL-6 ShMODS IL Rx Rx Rx Spyridaki A et al. Antimicrob Agents Chemother 2012; 56:
11 Comparative Survival until day 90 of Patients Enrolled RCT of clarithromycin 1g for 3 days (n=100) versus placebo (n=100) describing long-term mortality and costs Survival (%) Placebo Clarithromycin All cause mortality was 60% in placebo arm and 43% in C arm (p=0.023) 20 Comparisons day 29 to day 90 X 2 P-value 0 Log-rank (Mantel-Cox) Breslow (Generalised Wilcoxon) Tarone-Ware < < < Survival (days) Patients alive Placebo Clarithromycin Day Day Day Day Day Day Tsaganos T et al. Antimicrob Agents Chemother 2016; 60:
12 Comparative Cumulative Hospitalisation Cost Cumulative cost of hospitalisation ( ) Mean cumulative costs on day 25 (p=0.048) and on day 45 (p=0.011) were significantly different Placebo 100 patients Clarithromycin 100 patients P< Days of hospitalisation Tsaganos T et al. Antimicrob Agents Chemother 2016; 60:
13 Comparative Cumulative Hospitalisation Cost Cumulative cost of hospitalisation ( ) Placebo 51 patients Clarithromycin 62 patients P< Days of hospitalisation Tsaganos T et al. Antimicrob Agents Chemother 2016; 60:
14 Comparative Cumulative Hospitalisation Cost Antimicrobials patients Cumulative cost of hospitalisation ( ) Clarithromycin Placebo Days of hospitalisation Tsaganos T et al. Antimicrob Agents Chemother 2016; 60:
15 Comparative Cumulative Hospitalisation Cost Laboratory and Radiology patients Cumulative cost of hospitalisation ( ) Clarithromycin Placebo Days of hospitalisation Tsaganos T et al. Antimicrob Agents Chemother 2016; 60:
16 Comparative Cumulative Hospitalisation Cost Interventions patients Cumulative cost of hospitalisation ( ) Placebo Clarithromycin Days of hospitalisation Tsaganos T et al. Antimicrob Agents Chemother 2016; 60:
17 Comparative Cumulative Hospitalisation Cost Hospital beds patients Cumulative cost of hospitalisation ( ) Placebo Clarithromycin Days of hospitalisation Tsaganos T et al. Antimicrob Agents Chemother 2016; 60:
18 Cumulative Cost of Drugs other than Antimicrobials patients Cumulative cost of hospitalisation ( ) Placebo Clarithromycin P< Days of hospitalisation Tsaganos T et al. Antimicrob Agents Chemother 2016; 60:
19 Systemic Corticosteroid Treatment Chronic use Acute exacerbation of previous condition Treatment of new state Treatment of pneumonia Hospital admission New diagnosis HAP/VAP diagnosis Ranzani et al, Clin Pulm Med 2015; 22:
20 Ranzani OT et al. Critical Care Med 2012; 40: Corticosteroids Screened patients after daily rounds in 6 ICUs (n = 6 420) Patients with ICU-acquired pneumonia (n = 323) Patients analysed (n = 316) Not analysed (n = 07): Missing variables (n = 07) Without systemic steroid group (n = %) Systemic steroid group (n = %) NV-ICUAP (n = 81-42%) VAP (n = %) NV-ICUAP (n = 46-37%) VAP (n = 79-63%) Required intubation (n = 46-57%) Oxygen support (n = 35-43%) Required intubation (n = 32-70%) Oxygen support (n = 14-30%) 3 lost to follow-up after hospital discharge (censored) 0 lost to follow-up after hospital discharge (censored) Deaths at 28 days (n = 54-28%) Deaths at 28 days (n = 49-39%)
21 Characteristics of Corticosteroid Use on Diagnosis of ICU-acquired Pneumonia Indication n, (%) Exacerbation of respiratory diseases Neurological disorders Septic shock Long-term use of steroids Multiple reasons Others Administered drug n, (%) Methylprednisolone Dexamethasone Hydrocortisone Prednisolone Prevalence of long-term use, n (%) Cumulative dose, median (interquartile range) Length of treatment, days Total dose, mg Average daily dose, mg/day 41 (33) 34 (27) 18 (14) 12 (10) 11 (9) 9 (7) 67 (54) 34 (27) 22 (18) 2 (2) 29 (23) 6 (3-10) 380 ( ) 50 (34-142) Ranzani OT et al. Critical Care Med 2012; 40:
22 Outcome Variables No treatment (n = 191) Corticosteroid (n = 125) p Septic shock after diagnosis, n (%) Nonventilator ICU-acquired pneumonia that needed mechanical ventilation after diagnosis, n (%) 27 (14) 11 (9) (57) 32 (70) 0.22 Nonresponsive to treatment, n (%) Appropriate empiric treatment, n (%) 106 (56) 98 (83) 72 (58) 69 (78) Length of mechanical ventilation, d Median (IQR) 13 (7-22.5) 14 (9-24) 0.44 Mean ± SD 18 ± ± Ventilator-free days at 28, d Median (IQR) 3.5 ( ) 0 (0-21) 0.41 Mean ± SD 10 ± 11 9 ± Length of ICU stay, d Median (IQR) 16 (10-29) 15 (9.5-29) 0.96 Mean ± SD 22 ± ± Length of hospital stay, d Median (IQR) 37 (19-59) 38 (20-55) 0.89 Mean ± SD 45 ± ± Ranzani OT et al. Critical Care Med 2012; 40:
23 Ranzani OT et al. Critical Care Med 2012; 40: day Survival of Patients in ICU Survival Corticosteroids No treatment No. patients at risk Corticosteroids 125 No treatment Time (days since pneumonia diagnosis) Log-rank test: P value:
24 Ranzani OT et al. Critical Care Med 2012; 40: day Mortality - Cumulative Dosage of Corticosteroid Treatment of 125 patients with Previous Corticosteroids 1.0 Risk of 28-day mortality Propensity-adjusted association: Adj. HRL 1.610; 95% CI ; p = % IC Risk of death 95% IC Cumulative dosage of steroid (mg/d)
25 Days on Corticosteroid Treatment before Clinical Suspicion % CI Risk for high bacterial burden Adj: HR: 2.896; 95% CI ; p = (per 10 mg/day in methylprednisolone equivalent) Days on corticosteroid treatment before clinical suspicion 95% CI Ranzani OT et al. Critical Care Med 2012; 40:
26 Etiological Diagnosis of Pneumonia No treatment (n = 191) Corticosteroid (n = 125) p Any respiratory track sample, n (%) Etiologic diagnosis, n (%) Finally definite by: 182 (95) 116 (61) 118 (94) 88 (70) Tracheobronchial aspirates Invasive method Sputum Other Potentially drug-resistant bacteria, n (%) Polymicrobial pneumonia, n (%) 88 (77) 19 (16) 4 (3) 5 (4) 53 (28) 15 (8) 73 (83) 13 (15) 2 (2) - 34 (27) 13 (10) > Non-fermenting Gram-negative bacilli, n (%) Pseudomonas aeruginosa Enteric Gram-negative bacilli, n (%) Staphylococcus aureus, n (%) Methicillin sensitive Methicillin resistant 35 (18) 32 (17) 37 (19) 37 (19) 21 (11) 16 (8) 34 (27) 31 (25) 23 (18) 17 (14) 14 (11) 3 (2) > S. pneumoniae, n (%) H. influenzae, n (%) Other bacteria Aspergillus fumigatus, n (%) 4 (2) 7 (4) 9 (5) 1 (1) 5 (4) 1 (1) 7 (6) 5 (4) Ranzani OT et al. Critical Care Med 2012; 40:
27 Ranzani OT et al. Critical Care Med 2012; 40: Serum Levels of Inflammatory Biomarkers C-reactive protein day 1, mg/dl No treatment Corticosteroid p 15.6 ( ) 10.2 ( ) C-reactive protein day 3, mg/dl 12.5 ( ) 7.5 ( ) <0.001 Procalcitonin day 1, ng/ml 0.45 ( ) 0.30 ( ) Procalcitonin day 3, ng/ml 0.38 ( ) 0.21 ( ) Midregional proadrenomedullin day 1, nmol/l 1.38 ( ) 1.10 ( ) 0.19 Midregional proadrenomedullin day 3, nmol/l 1.39 ( ) 0.96 ( ) IL-6 day 1, pg/ml 192 (84-492) 94 (24-239) <0.001 IL-6 day 3, pg/ml 104 (54-275) 56 (13-149) IL-8 day 1, pg/ml 104 (63-205) 79 (52-162) 0.10 IL-8 day 3, pg/ml 85 (42-168) 79 (45-162) 0.96 Tumour necrosis factor-α day 1, pg/ml 9 (5-16) 6 (4-9) Tumour necrosis factor-α day 3, pg/ml 9 (6-19) 6 (4-11) 0.003
28 Total admissions in ICU (01/01/ /01/2013) n = 5923 Statins Total suspected VAP episodes (01/01/ /01/2013) n = 631 Total analysed suspected VAP episodes n = 349 Excluded because: Inclusion into a clinical trial testing statins (n=52) Missing data (n=22) CPIS < 5 points and ATB D1 = 0 (n=208) n = 282 Statin naïve patients n = 256 Statin previous users n = 93 Drug discontinued after ICU admission n = 41 Drug continued after ICU admission n = 52 Bruyere R et al. Critical Care 2014; 18: R83
29 Survival of Patients with Suspected VAP Prior Statin Use Naïve patients Cumulative survival Previous users Time elapsed since VAP onset (days) Bruyere R et al. Critical Care 2014; 18: R83
30 Independent Predictors of 30-day Mortality in Patients with Suspected VAP Hazard ratio 95% CI P Steroids during VAP <0.01 Cirrhosis <0.01 Age <0.01 SAPS II <0.01 SOFA day <0.01 Statin prior exposure Bruyere R et al. Critical Care 2014; 18: R83
31 Patients with Suspected VAP Drug Continuation Statin continuation Cumulative survival Statin discontinuation Time elapsed since VAP onset (days) Bruyere R et al. Critical Care 2014; 18: R83
32 Independent Predictors of 30-day Death in the Statin Previous Users Subset of Patients with Suspected VAP Hazard ratio 95% CI P Age <0.01 SOFA day 1 value Statin continuation after ICU admission Bruyere R et al. Critical Care 2014; 18: R83
33 Independent Predictors of 30-day Death in the Statin Previous Users Subset of Patients with Clinically Suspected VAP and Tracheal Aspirate Positive Culture Hazard ratio 95% CI P Age <0.01 SOFA day 1 value <0.01 Statin continuation after ICU admission Bruyere R et al. Critical Care 2014; 18: R83
34 1303 Patients assessed for eligibility 1003 Excluded 150 Elevated ALT, AST, or CK level 149 Statins given after intubation 118 Previous VAP episode 110 Enrolled in another trial within 30 days 79 Decision for treatment limitation 77 Treatment contraindicating statins 55 Terminal illness 50 Liver failure 41 ICU too busy 30 Next of kin declined consent 30 Organisational failure 29 Bone marrow asplasia 29 Continuous gastric tube aspiration 21 No gastric tube 8 Younger than 18 years 2 Pregnant 25 Other 300 Randomised 147 Randomised to receive simvastatin (60mg) 147 Received simvastatin as randomised 147 Randomised to receive placebo 147 Received placebo as randomised 147 Included in analysis 7 Excluded 4 Withdrew consent 3 Denied consent 138 Included in analysis 9 Excluded 6 Withdrew consent 3 Denied consent Papazian L et al. JAMA 2013; 310:
35 Proportions of Non-survivors 25 Probability of death, % Simvastatin Placebo 0 0 No. at risk Simvastatin 146 Placebo Time from randomisation (days) Papazian L et al. JAMA 2013; 310:
36 Main Study Outcomes No. (%) [95% CI] Outcome Simvastatin (n = 146) Placebo (n = 146) Between-Group Difference, % (95% CI) P Mortality Day 28 (primary outcome) 31 (21) [15, 29] 21 (15) [10, 22] 6 (-3, 15) 0.10 Day (15) [10, 22] 16 (12) [7, 18] 3 (-5. 11) 0.39 ICU 38 (26) [20, 34] 30 (22) [16, 29] 4 (-5, 14) 0.40 Hospital 43 (30) [23, 37] 38 (28) [21, 36] 2 (-8. 12) 0.72 Papazian L et al. JAMA 2013; 310:
37 Nebulised Antibiotics in MV Patients The safety of nebulization of antibiotics has been proven in numerous studies Efficacy as adjunctive treatment to intravenous regimens or as monotherapy has been demonstrated in ventilator-associated pneumonia or ventilatorassociated tracheobronchitis due to MDR or susceptible pathogens However, due to the heterogeneity of studies, multiple meta-analyses fail to demonstrate a clear effect Clarification of indications, standardisation of technique and implementation of clinical practice guidelines, based on new large-scale trials will lead to the optimal use of nebulized antibiotics Poulakou G et al. Expert Rev Anti Infect Ther 2017 [E-Pub]
38 Role of Aerosolised Colistin in VAP: Systematic Review and Meta-analysis Potentially relevant studies identified and screened for retrieval from electronic search: 361 Studies excluded on basis of title or abstract: 328 Studies retrieved in full text: 33 Studies included in the systematic review: 16 Studies excluded based on exclusion criteria: 17 No clear definition of VAP: 4 Reviews: 3 Less than 5 patients: 3 No separate data on AS colistin: 2 No separate data on VAP: 2 No data on outcomes of interest: 1 Use of AS polymyxin B: 1 Patients with ventilator-assisted tracheobronchitis: 1 Single-arm studies (systematic review only): 8 Comparative studies (meta-analysis): 8 Valachis A et al. Crit Care Med 2015; 43:
39 Clinical Response: IV Colistin versus AS and IV Colistin Adjunctive AS colistin IV colistin Odds Ratio Odds Ratio Study or subgroup Events Total Events Total Weight M-H Fixed 95% CI M-H Fixed 95% CI Doshi 2013 Kalin 2012 Kofteridis 2010 Korbila 2010 Naesens 2011 Péres-Pedrero 2011 Rattanaumpawan 2010 Tumbarello % 11.1% 11.7% 11.2% 0.9% 1.3% 21.2% 28.7% 1.86 (0.82, 4.21) 0.24 (0.05, 1.05) 1.56 (0.62, 3.94) 2.53 (1.11, 5.76) 5.25 (0.49, 5.80) 3.00 (0.26, 34.57) 0.92 (0.42, 2.02) 1.86 (1.05, 3.27) Total events (95% CI) Total events % 1.57 (1.14, 2.15) Heterogeneity: Chi 2 = 11.05, df = 7 (P = 0.14). I 2 = 37% Test for overall effect: Z = 2.77 (P = 0.006) Favours IV colistin Favours AS + IV colistin Valachis A et al. Crit Care Med 2015; 43:
40 Overall Mortality: IV Colistin versus AS and IV Colistin AS + IV colistin IV colistin Odds Ratio Odds Ratio Study or subgroup Events Total Events Total Weight M-H Fixed 95% CI M-H Fixed 95% CI Doshi 2013 Kalin 2012 Kofteridis 2010 Korbila 2010 Naesens 2011 Rattanaumpawan 2010 Tumbarello % 4.5% 14.9% 16.0% 4.8% 11.5% 29.4% 0.46 (0.20, 1.06) 1.41 (0.40, 4.91) 0.42 (0.17, 1.07) 0.83 ( ) 0.05 (0.00, 1.17) 1.10 (0.50, 2.44) 0.89 (0.51, 1.54) Total events (95% CI) Total events % 0.74 (0.54, 1.01) Heterogeneity: Chi 2 = 7.98, df = 6 (P = 0.24). I 2 = 25% Test for overall effect: Z = 1,88 (P = 0.06) Favours AS + IV colistin Favours IV colistin 100 Valachis A et al. Crit Care Med 2015; 43:
41 Anti-inflammatory Therapy in VAP Macrolides - may accelerate resolution of VAP and weaning from MV in surviving patients and delaying death in those who die of sepsis and possibly offer long-term survival benefit and reduction of costs of hospitalisation Corticosteroids - should be used cautiously in ICU patients since this treatment is strongly associated with increased risk of death in ICU-acquired pneumonia Statins - prior use and continuation in ICU, after adjusting for confounders, was associated with better survival in VAP patients while adjunctive statin therapy in patients with suspected VAP did not improve 28-day survival
42 CS Adjunctive Therapy in Children Paediatric severe sepsis (ICD-9 plus mechanical ventilation and vasoactive infusions) overall mortality was 24% and use of CS, older age and haematologic-oncologic diagnoses were independent predictors of mortality History of CS use in clinical medicine has been colourful, noisy and always controversial and the safety and efficacy of CS as a general adjunctive therapy for paediatric septic shock has not been established Assessment of adjunctive CS on genome response in paediatric septic shock documented that genes corresponding to adaptive immunity-related signalling were down-regulated significantly in the CS relative to controls, with a similar pattern with genes corresponding to glucocorticoid receptor signalling pathways Markovitz BP et al. Pediatr Crit Care Med 2005; 6: Zimmerman JJ et al. Pediatr Crit Cae Med 2007; 8: Wong HR et al. Am J Respir Crit Care Med 2014; 189:
43 CS Adjunctive Therapy in Children All steroid drug classes posses biological plausibility to offer a beneficial clinical effect among children with septic shock, but none has undergone rigorous, prospective assessment in a large, high-quality paediatric interventional trial Zimmerman JJ. Pediatr Clin North Am 2017; 64:
44 Statin Adjunctive Therapy in Children Kawasaki disease is treated in 10-20% of children with IVIG and have an almost 9-fold increased risk of CAA Approximately 80-90% of children who go on to CAA have abnormal coronary artery dimension on their first echo which can identify high-risk cases Additional adjunctive therapies suggested include CS, TNF inhibitors, calcineurin inhibitors and IL-1 blockers Animal studies have suggested that statins may be beneficial in blocking CAA progress but it is unlikely that these therapies will be studied in large randomised controlled trials due to sample size and funding constraints Campbell AJ et al. J Infect 2016; 72 suppl: S1-S5
45 Colistin Adjunctive Therapy in Children Aerosolised colistin (5mg/kg base activity of aerosolised colistin methanesulfonate every 12h for 14, 14, and 16 days) in two pre-term and one term neonate with Acinetobacter baumannii and Pseudomonas aeruginosarelated VAP unresponsive to previous antibiotics was found to be safe and tolerable Aerosolised colistin (1,000,000 IU (33.4mg) twice daily) as monotherapy for pre-term infants with A. baumannii-related VAP were cured with no clinical or laboratory adverse events Both authors indicate the need for larger, controlled trials to establish the dose and corroborate the findings Celik IH et al. Eur J Pediatr 2012; 171: Kang CH et al. Perdiatr Pulmonol 2014; 49:
46 Pulmozyme Adjunctive Therapy in Children Prospective, randomised, blinded pilot study to compare adjunctive dornase alfa therapy (2.5mg nebulised via ETT) to sham therapy in infants with VAPI showed a trend to decreased oxygen requirements which did not reach statistical significance with no side effects Scala M et al. Pediatr Pulmonol 2017; 52:
47 Increasing antibiotic consumption Greater infection related patient morbidity and mortality Greater emergence of antibiotic resistance Increased administration of inappropriate initial therapy Kollef M. Chest 2016 [E-pub]
HEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY
HEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics, & Epidemiology Associate Chief Medical Officer, UNC Health
More informationCURRENT GUIDELINES FOR SEPSIS MANAGEMENT
HELLENIC SEPSIS STUDY GROUP www.sepsis.gr CURRENT GUIDELINES FOR SEPSIS MANAGEMENT Evangelos J. Giamarellos-Bourboulis, MD, PhD Associate Professor of Medicine 4 th Department of Internal Medicine, National
More informationGuess or get it right?
Guess or get it right? Antimicrobial prescribing in the 21 st century Robert Masterton Traditional Treatment Paradigm Conservative start with workhorse antibiotics Reserve more potent drugs for non-responders
More informationwithout the permission of the author Not to be copied and distributed to others
Emperor s Castle interior-prato What is the Role of Inhaled Polymyxins for Treatment of Respiratory Tract Infections? Helen Giamarellou CONCLUSIONS: Patients with Pseudomonas and Acinetobacter VAP may
More informationCommunity Acquired & Nosocomial Pneumonias
Community Acquired & Nosocomial Pneumonias IDSA/ATS 2007 & 2016 Guidelines José Luis González, MD Clinical Assistant Professor of Medicine Outline Intro - Definitions & Diagnosing CAP treatment VAP & HAP
More informationSteroid in Paediatric Sepsis. Dr Pon Kah Min Hospital Pulau Pinang
Steroid in Paediatric Sepsis Dr Pon Kah Min Hospital Pulau Pinang Contents Importance of steroid in sepsis Literature Review for adult studies Literature Review for paediatric studies Conclusions. Rationale
More informationCorticosteroids in Severe CAP. Mervyn Mer Department of Medicine & ICU Johannesburg Hospital University of the Witwatersrand
Corticosteroids in Severe CAP Mervyn Mer Department of Medicine & ICU Johannesburg Hospital University of the Witwatersrand Introduction Much controversy and debate regarding the use of corticosteroids
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Blum CA, Nigro N, Briel M, et al. Adjunct prednisone
More informationPolmoniti: Steroidi sì, no, quando. Alfredo Chetta Clinica Pneumologica Università degli Studi di Parma
Polmoniti: Steroidi sì, no, quando Alfredo Chetta Clinica Pneumologica Università degli Studi di Parma Number of patients Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive
More informationDiagnosis of Ventilator- Associated Pneumonia: Where are we now?
Diagnosis of Ventilator- Associated Pneumonia: Where are we now? Gary French Guy s & St. Thomas Hospital & King s College, London BSAC Guideline 2008 Masterton R, Galloway A, French G, Street M, Armstrong
More informationIntracheal antibiotics administration
Intracheal antibiotics administration Jean Chastre, M.D. www.reamedpitie.com Disclosure Conflicts of interest: Consulting or Lecture fees: Bayer, Pfizer, Cubist/Merck, Basilea, Kenta/Aridis, Roche, AstraZeneca/Medimmune
More informationEducational Workshop
Educational Workshop EW02: Management of severe sepsis and septic shock anno 2015 Arranged with ESGBIS & International Sepsis Forum (ISF) Convenors: W. Joost Wiersinga, Amsterdam, NL Tom van der Poll,
More informationMarcos I. Restrepo, MD, MSc, FCCP
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More information[No conflicts of interest]
[No conflicts of interest] Patients and staff at: Available evidence pre-calories Three meta-analyses: Gramlich L et al. Does enteral nutrition compared to parenteral nutrition result in better outcomes
More informationCharles Feldman. Charlotte Maxeke Johannesburg Academic Hospital University of the Witwatersrand
Opportunistic Infections Community Acquired Pneumonia Charles Feldman Professor of Pulmonology and Chief Physician Charlotte Maxeke Johannesburg Academic Hospital University of the Witwatersrand Introduction
More informationHerpes virus reactivation in the ICU. M. Ieven BVIKM
Herpes virus reactivation in the ICU M. Ieven BVIKM 07.04.2011 Introduction: Viruses identified in critically ill ICU patients Viral diseases have recently been the subject of numerous investigations in
More informationUPDATE IN HOSPITAL MEDICINE
UPDATE IN HOSPITAL MEDICINE FLORIDA CHAPTER ACP MEETING 2016 Himangi Kaushal, M.D., F.A.C.P. Program Director Memorial Healthcare System Internal Medicine Residency DISCLOSURES None OBJECTIVES Review some
More informationTerapia della candidiasi addomaniale
Verona 16 marzo 2018 Terapia della candidiasi addomaniale Pierluigi Viale Infectious Disease Unit Teaching Hospital S. Orsola Malpighi Bologna INTRA ABDOMINAL CANDIDIASIS open questions a single definition
More informationUsefulness of Procalcitonin in the management of Infections in ICU. P Damas CHU Sart Tilman Liège
Usefulness of Procalcitonin in the management of Infections in ICU P Damas CHU Sart Tilman Liège Procalcitonin Peptide 116 AA Produced by parenchymal cells during «sepsis»: IL1, TNF, IL6 : stimulators
More informationDisclosures. Objectives. Procalcitonin: Pearls and Pitfalls in Daily Practice
Procalcitonin: Pearls and Pitfalls in Daily Practice Sarah K Harrison, PharmD, BCCCP Clinical Pearl Disclosures The author of this presentation has no disclosures concerning possible financial or personal
More informationDr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher
Professor Richard Beasley University of Otago Director Medical Research Institute of New Zealand Wellington Dr Sarah Mooney Physiotherapy Advanced Clinician Counties Manukau Health NZ Respiratory and Sleep
More informationVentilator Associated Pneumonia. ICU Fellowship Training Radboudumc
Ventilator Associated Pneumonia ICU Fellowship Training Radboudumc Attributable mortality VAP Meta-analysis of individual patient data from randomized prevention studies Attributable mortality mainly results
More informationInhaled Antibiotics in Non-CF. Dr Michael Loebinger Host Defence Unit Royal Brompton Hospital London, United Kingdom
Inhaled Antibiotics in Non-CF Dr Michael Loebinger Host Defence Unit Royal Brompton Hospital London, United Kingdom Advantages Increased drug concentrations locally Reduced systemic adverse effects Home
More informationBiomarkers in sepsis. Dr S Omar University of Witwatersrand CHBAH Bara ICU
Biomarkers in sepsis Dr S Omar University of Witwatersrand CHBAH Bara ICU Procalcitonin PCT biomarker 1993- described as a sepsis associated protein Identical to the precursor protein of calcitonin which
More informationBack to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill
Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Joe Palumbo PGY-2 Critical Care Pharmacy Resident Buffalo General Medical Center Disclosures
More informationSupplementary Online Content
Supplementary Online Content Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory
More informationHow do we define pneumonia?
Robert L. Keith MD FCCP Associate Professor of Medicine Division of Pulmonary Sciences & Critical Care Medicine Denver VA Medical Center University of Colorado Denver How do we define pneumonia? Fever
More informationPAEDIATRIC RESPIRATORY FAILURE. Tang Swee Fong Department of Paediatrics University Kebangsaan Malaysia Medical Centre
PAEDIATRIC RESPIRATORY FAILURE Tang Swee Fong Department of Paediatrics University Kebangsaan Malaysia Medical Centre Outline of lecture Bronchiolitis Bronchopulmonary dysplasia Asthma ARDS Bronchiolitis
More informationSteroids for ARDS. Clinical Problem. Management
Steroids for ARDS James Beck Clinical Problem A 60 year old lady re-presented to ICU with respiratory failure. She had previously been admitted for fluid management and electrolyte correction having presented
More informationANWICU knowledge
ANWICU knowledge www.anwicu.org.uk This presenta=on is provided by ANWICU We are a collabora=ve associa=on of ICUs in the North West of England. Permission to provide this presenta=on has been granted
More informationStressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU
Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds November 8, 2016 2016 MFMER slide-1 Objectives Identify the significance
More informationPotential Conflicts of Interests
Potential Conflicts of Interests Research Grants Agency for Healthcare Research and Quality Akers Bioscience, Inc. Pfizer, Inc. Scientific Advisory Boards Pfizer, Inc. Cadence Pharmaceuticals Kimberly
More informationInfections In Cirrhotic patients. Dr Abid Suddle Institute of Liver Studies King s College Hospital
Infections In Cirrhotic patients Dr Abid Suddle Institute of Liver Studies King s College Hospital Infection in cirrhotic patients Leading cause morbidity/mortality Common: 30-40% of hospitalised cirrhotic
More informationHAP/VAP care bundle interventions - a UK approach. Dr R G Masterton NHS Ayrshire & Arran
HAP/VAP care bundle interventions - a UK approach Dr R G Masterton NHS Ayrshire & Arran How Hazardous Is Health Care? (Leape and Amalberti) Total lives lost per year 100,000 10,000 1,000 100 10 1 HAZARDOUS
More informationSteroids in ARDS: if, when, how much? John Fowler, MD, FACEP Dept. of Emergency Medicine Kent Hospital, İzmir, Türkiye
Steroids in ARDS: if, when, how much? John Fowler, MD, FACEP Dept. of Emergency Medicine Kent Hospital, İzmir, Türkiye Steroids in ARDS: conclusion Give low-dose steroids if indicated for another problem
More informationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 Mitchell M. Levy MD, MCCM Professor of Medicine Chief, Division of Pulmonary, Sleep, and Critical Care
More informationYear in Review Intensive Care Training Program Radboud University Medical Centre Nijmegen
Year in Review 2013 Intensive Care Training Program Radboud University Medical Centre Nijmegen Contents ARDS Ventilator associated pneumonia Tracheostomy and endotracheal intubation Enteral feeding Fluid
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia Paladino J A, Gudgel L D, Forrest A, Niederman
More informationEFFECT OF EARLY VASOPRESSIN VS NOREPINEPHRINE ON KIDNEY FAILURE IN PATIENTS WITH SEPTIC SHOCK. Alexandria Rydz
EFFECT OF EARLY VASOPRESSIN VS NOREPINEPHRINE ON KIDNEY FAILURE IN PATIENTS WITH SEPTIC SHOCK Alexandria Rydz BACKGROUND- SEPSIS Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationGuidelines 2017 for the management of hospitalacquired pneumonia (HAP) and. ventilator-associated. pneumonia (VAP)
Guidelines 2017 for the management of hospitalacquired pneumonia (HAP) and ventilator-associated Modifiez le style des sous-titres du masque pneumonia (VAP) Filip Moerman Présentation pour les soins int
More informationMDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES
MDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES 1 Marin H. Kollef, MD Professor of Medicine Virginia E. and Sam J. Golman Chair in Respiratory Intensive Care Medicine Washington University School of
More informationVentilator Associated Pneumonia. ICU Fellowship Training Radboudumc
Ventilator Associated Pneumonia ICU Fellowship Training Radboudumc Attributable mortality VAP Meta-analysis of individual patient data from randomized prevention studies Attributable mortality mainly results
More informationSuperhero or Superzero? Vancomycin vs. Linezolid for MRSA Pneumonia
Superhero or Superzero? Vancomycin vs. Linezolid for MRSA Pneumonia Brandon Dionne, PharmD, BCPS, AAHIVP Assistant Clinical Professor Northeastern University Seth Housman, PharmD, MPA Clinical Assistant
More informationDose-dependent effects of tobramycin in an animal model of Pseudomonas sinusitis Am J Rhino Jul-Aug; 21(4):423-7
AMINOGLYCOSIDES Dose-dependent effects of tobramycin in an animal model of Pseudomonas sinusitis Am J Rhino. 2007 Jul-Aug; 21(4):423-7 http://www.ncbi.nlm.nih.gov/pubmed/17882910 Evaluation of the in-vivo
More informationTerapia delle infezioni da Pseudomonas aeruginosa MDR
Verona 23 ottobre 2010 Terapia delle infezioni da Pseudomonas aeruginosa MDR Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Global resistance surveillance of Pseudomonas aeruginosa
More informationCOPD exacerbation. Dr. med. Frank Rassouli
Definition according to GOLD report: - «An acute event - characterized by a worsening of the patients respiratory symptoms - that is beyond normal day-to-day variations - and leads to a change in medication»
More informationManagement of Acute Exacerbations
15 Management of Acute Exacerbations Cenk Kirakli Izmir Dr. Suat Seren Chest Diseases and Surgery Training Hospital Turkey 1. Introduction American Thoracic Society (ATS) and European Respiratory Society
More informationThe Use of Metabolic Resuscitation in Sepsis
The Use of Metabolic Resuscitation in Sepsis Jennifer M. Roth, PharmD, BCPS, BCCCP Critical Care Clinical Specialist - Surgical Trauma ICU Baylor University Medical Center Disclosures No conflicts of interest
More informationPresented at the annual meeting of the American Society of Microbiology, June 1-5, 2017, New Orleans, LA, USA
Is Associated With Improved Survival and Safety Compared to Colistin in Serious Carbapenemresistant Enterobacteriaceae (CRE) Infections: Results of the CARE Study Lynn E. Connolly 1, Adrian M. Jubb 1,
More informationSerious MRSA infection: anything new?
Serious MRSA infection: anything new? Professor Mark H. Wilcox Leeds Teaching Hospitals & University of Leeds, UK Public Health England & NHS Improvement Potential Conflicts of Interest I have received:
More informationPrevention of Nosocomial Infections in Critically Ill Patients with Lactoferrin (PREVAIL) Study
Prevention of Nosocomial Infections in Critically Ill Patients with Lactoferrin (PREVAIL) Study A Randomized Double Blind Phase II Study Dr. John Muscedere, Queen s University, Kingston, Canada Co-Investigators:
More informationObjectives. Pathophysiology of Steroids. Question 1. Pathophysiology 3/1/2010. Steroids in Septic Shock: An Update
Objectives : An Update Michael W. Perry PharmD, BCPS PGY2 Critical Care Resident Palmetto Health Richland Hospital Review the history of steroids in sepsis Summarize the current guidelines for steroids
More informationJournal Club The ELITE Trial. Sandra Katalinic, Pharmacy Resident University Hospital of Northern British Columbia April 28, 2010
Journal Club The ELITE Trial Sandra Katalinic, Pharmacy Resident University Hospital of Northern British Columbia April 28, 2010 Overview Journal article Title, journal, authors, funding Abstract Introduction
More informationCHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement
CHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement Evidence-Based Assessment of Diagnostic Tests for Ventilator- Associated Pneumonia* Executive Summary Ronald F. Grossman, MD, FCCP; and Alan Fein, MD,
More informationAntisepsis Bath and Oral.. Should We Change Practice? DR AZMIN HUDA ABDUL RAHIM
Antisepsis Bath and Oral.. Should We Change Practice? DR AZMIN HUDA ABDUL RAHIM Chlorhexidine Exposure in ICU Chlorhexidine gluconate Long acting topical antiseptic In use since 1954 Water soluble Remains
More informationPneumonia (PNEU) and Ventilator-Associated Pneumonia (VAP) Prevention. Basics of Infection Prevention 2-Day Mini-Course 2016
Pneumonia (PNEU) and Ventilator-Associated Pneumonia (VAP) Prevention Basics of Infection Prevention 2-Day Mini-Course 2016 Objectives Differentiate long term care categories of respiratory infections
More informationThe Clinical Management of Hospital Acquired Pneumonia. NHS Ayrshire & Arran
The Clinical Management of Hospital Acquired Pneumonia Dr R G Masterton NHS Ayrshire & Arran What s new in HAP/VAP? Care bundles MRSA VAP Improving outcomes with current antimicrobial New antimicrobials
More informationNew Surveillance Definitions for VAP
New Surveillance Definitions for VAP 2012 Critical Care Canada Forum Toronto Dr. John Muscedere Associate Professor of Medicine, Queen s University Kingston, Ontario Presenter Disclosure Dr. J. G. Muscedere
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSepsis Management: Past, Present, and Future
Sepsis Management: Past, Present, and Future Benjamin Ferrell, MD Tennessee ACP Meeting October 28, 2017 Learning Objectives Identify the most updated definition and clinical criteria for sepsis Describe
More informationBrice Taylor Assistant Professor Division of Pulmonary and Critical Care Medicine
Brice Taylor Assistant Professor Division of Pulmonary and Critical Care Medicine Discuss advances in predicting prognosis Understand dwhat we know (and don t know) about the Microbiology Recognize important
More information(See the editorial commentary by Paterson and Rogers, on pages )
MAJOR ARTICLE Aerosolized plus Intravenous Colistin versus Intravenous Colistin Alone for the Treatment of Ventilator-Associated Pneumonia: A Matched Case-Control Study Diamantis P. Kofteridis, 1 Christina
More informationBest of Pulmonary Jennifer R. Hucks, MD University of South Carolina School of Medicine
Best of Pulmonary 2012-2013 Jennifer R. Hucks, MD University of South Carolina School of Medicine Topics ARDS- Berlin Definition Prone Positioning For ARDS Lung Protective Ventilation In Patients Without
More informationPredicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
More informationMichael S. Niederman, M.D. Clinical Director Pulmonary and Critical Care Medicine New York Presbyterian Hospital Weill Cornell Medical Center
CA-MRSA Pneumonia Michael S. Niederman, M.D. Clinical Director Pulmonary and Critical Care Medicine New York Presbyterian Hospital Weill Cornell Medical Center Professor of Clinical Medicine Weill Cornell
More informationApproach to Severe Sepsis. Jan Hau Lee, MBBS, MRCPCH. MCI Children s Intensive Care Unit KK Women s and Children's Hospital, Singapore
Approach to Severe Sepsis Jan Hau Lee, MBBS, MRCPCH. MCI Children s Intensive Care Unit KK Women s and Children's Hospital, Singapore 1 2 No conflict of interest Overview Epidemiology of Pediatric Severe
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationSeptic Shock. Rontgene M. Solante, MD, FPCP,FPSMID
Septic Shock Rontgene M. Solante, MD, FPCP,FPSMID Learning Objectives Identify situations wherein high or low BP are hemodynamically significant Recognize complications arising from BP emergencies Manage
More informationAcute Lung Injury/ARDS. Disclosures. Overview. Acute Respiratory Failure 5/30/2014. Research funding: NIH, UCSF CTSI, Glaxo Smith Kline
Disclosures Acute Respiratory Failure Carolyn S. Calfee, MD MAS UCSF Critical Care Medicine and Trauma CME May 30, 2014 Research funding: NIH, UCSF CTSI, Glaxo Smith Kline Medical advisory boards: Cerus
More informationWhy we need inhaled antibiotics?
Athens 19-20 November 2015 Why we need inhaled antibiotics? Garyfallia Poulakou Consultant, Infectious Diseases 4 th Dept of Internal Medicine, Attikon University Hospital of Athens TRANSPARENCY DECLARATION
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationIs inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii?
DOI 10.1186/s12941-016-0123-7 Annals of Clinical Microbiology and Antimicrobials RESEARCH Open Access Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by
More informationEnterobacter aerogenes
Enterobacter aerogenes Piagnerelli M 1, Carlier E 1, Deplano A 3, Lejeune P 1, Govaerts D 2 1 Departments of Intensive Care and 2 Microbiology, A. Vésale Hospital. 6110 Montigny-le-Tilleul. 3 Department
More informationStatins in lung disease
Statins in lung disease Associate Professor Robert Young BMedSc, MBChB, DPhil (Oxon), FRACP, FRCP University of Auckland, New Zealand Smoking and its complications Respiratory COPD Cardiovascular CAD Smoking
More informationBiomarkers in sepsis: Utility in critical care
Biomarkers in sepsis: Utility in critical care Fathima Paruk, PhD Charlotte Maxeke Johannesburg Academic Hospital and University of Witwatersrand Kumar A et al, Chest 2009; 136:1237-48. von Gunten et al
More informationResearch Article Eosinophil as a Protective Cell in S. aureus Ventilator-Associated Pneumonia
Hindawi Publishing Corporation Mediators of Inflammation Volume 2013, Article ID 152943, 5 pages http://dx.doi.org/10.1155/2013/152943 Research Article Eosinophil as a Protective Cell in S. aureus Ventilator-Associated
More informationSeptic shock in children. Is it different than adults? Peter Kanizsai, MD, PhD associate professor in emergency medicine
Septic shock in children. Is it different than adults? Peter Kanizsai, MD, PhD associate professor in emergency medicine http://www.ipaustralia.com.au/applicant/clinical-excellence-commission/trademarks/1473265/
More informationThe Ever Changing World of Sepsis Management. Laura Evans MD MSc Medical Director of Critical Care Bellevue Hospital
The Ever Changing World of Sepsis Management Laura Evans MD MSc Medical Director of Critical Care Bellevue Hospital COI Disclosures No financial interests to disclose Learning Objectives Review the evolution
More informationAntibiotics for ventilator-associated pneumonia(review)
Cochrane Database of Systematic Reviews Antibiotics for ventilator-associated pneumonia(review) ArthurLE,KizorRS,SelimAG,vanDrielML,SeoaneL ArthurLE,KizorRS,SelimAG,vanDrielML,SeoaneL. Antibiotics for
More informationLinezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin Shorr A F, Susla G M, Kollef M H
Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin Shorr A F, Susla G M, Kollef M H Record Status This is a critical abstract of an economic evaluation
More informationPneumonia in the Hospitalized
Pneumonia in the Hospitalized Patient: Use of Steroids Nicolette Myers, MD Pulmonary/Sleep/Critical Care November 9, 2018 Park Nicollet Clinic Facts About Pneumonia CAP is the 8 th most common cause of
More informationIntravenous Vitamin C. Severe Sepsis Acute Lung Injury
Intravenous Vitamin C Severe Sepsis Acute Lung Injury Alpha A. (Berry) Fowler, III, MD Professor of Medicine VCU Pulmonary Disease and Critical Care Medicine I Have No Disclosures Bacterial Sepsis Approximately
More informationAvian Influenza A (H7N9): Clinical Management. KW Choi Associate Consultant IDCTC, HA/ ICB, CHP
Avian Influenza A (H7N9): Clinical Management KW Choi Associate Consultant IDCTC, HA/ ICB, CHP Initial symptoms: nonspecific, similar to most other causes of ILI, CAP High index of suspicion and alertness
More informationEarly Rehabilitation in the ICU: Do We Still Need Chest Physiotherapy?
Early Rehabilitation in the ICU: Do We Still Need Chest Physiotherapy? Michelle Kho, PT, PhD Assistant Professor, School of Rehabilitation Science, McMaster University Adjunct Assistant Professor, Department
More informationSepsis Update: Focus on Early Recognition and Intervention. Disclosures
Sepsis Update: Focus on Early Recognition and Intervention Jessie Roske, MD October 2017 Disclosures I have no actual or potential conflict of interest in relation to this program/presentation. I will
More informationDex single dose Pred- 5 day course Mean Difference Mean Difference Mean 3.5. Weight 100.0% IV, Fixed, 95% CI [-1.97, 0.37] 100.
Question : In the child with asthma exacerbation in the ED should prednisolone/prednisone vs. dexamethasone be used to prevent hospitalization, decrease time in the ED or improve pulmonary function? Forest
More informationThe Potential For Microbiome Modification In Critical Illness. Deborah Cook
The Potential For Microbiome Modification In Critical Illness Deborah Cook To review Objectives The microbiome & concepts about its modification during critical illness Interventions Predisposition to
More informationPotenzialità Terapeutiche delle Immunoglobuline
Potenzialità Terapeutiche delle Immunoglobuline AGENDA # Guidelines and Evidences # Ig and Pathobiology of Sepsis # Ideas and Data slides and discussion girardis.massimo@unimo.it Disclosures POTENTIAL
More informationPneumonia Severity Scores:
Pneumonia Severity Scores: Are they Accurate Predictors of Mortality? JILL McEWEN, MD FRCPC Clinical Professor Department of Emergency Medicine University of British Columbia Vancouver, BC Canada President,
More informationFluid Treatments in Sepsis: Meta-Analyses
Fluid Treatments in Sepsis: Recent Trials and Meta-Analyses Lauralyn McIntyre MD, FRCP(C), MSc Scientist, Ottawa Hospital Research Institute Assistant Professor, University of Ottawa Department of Epidemiology
More informationEffect of Clarithromycin in Patients with Sepsis and Ventilator-Associated Pneumonia
MAJOR ARTICLE Effect of Clarithromycin in Patients with Sepsis and Ventilator-Associated Pneumonia Evangelos J. Giamarellos-Bourboulis, 1 Jean-Claude Pechère, 4 Christina Routsi, 2 Diamantis Plachouras,
More informationAntimicrobial Stewardship in Community Acquired Pneumonia
Antimicrobial Stewardship in Community Acquired Pneumonia Medicine Review Course 2018 Dr Lee Tau Hong Consultant Department of Infectious Diseases National Centre for Infectious Diseases Scope 1. Diagnosis
More informationARTICLE IN PRESS. International Journal of Antimicrobial Agents xxx (2008) xxx xxx. Contents lists available at ScienceDirect
International Journal of Antimicrobial Agents xxx (2008) xxx xxx Contents lists available at ScienceDirect International Journal of Antimicrobial Agents journal homepage: http://www.elsevier.com/locate/ijantimicag
More informationKey Points. Angus DC: Crit Care Med 29:1303, 2001
Sepsis Key Points Sepsis is the combination of a known or suspected infection and an accompanying systemic inflammatory response (SIRS) Severe sepsis is sepsis with acute dysfunction of one or more organ
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients
More informationEndocrine and Metabolic Complications in the ICU
Endocrine and Metabolic Complications in the ICU Linda Liu, M.D. Associate Professor UCSF Department of Anesthesia UC SF 1 New Progress Discovery of complex neuro-endocrine adaptation to critical illness
More informationLa farmacologia in aiuto
Ferrara, 15 giugno 2018 La farmacologia in aiuto Pier Giorgio Cojutti, Federico Pea Istituto di Farmacologia Clinica Azienda Sanitaria Universitaria Integrata di Udine Therapeutic Drug Monitoring of Beta-Lactams
More informationTreatment of multi drug resistant gram negative bacilli with inhaled polymyxin-b
Treatment of multi drug resistant gram negative bacilli with inhaled polymyxin-b Suresh Kumar Konkyana 1. Anil Kumar Akkenapalli 2 Assistant Professor, Department of Anesthesiology, Osmania Medical College/MGMH,
More informationCORTICOSTEROID USE IN SEPTIC SHOCK THE ONGOING DEBATE DIEM HO, PHARMD PGY1 PHARMACY RESIDENT VALLEY BAPTIST MEDICAL CENTER BROWNSVILLE
CORTICOSTEROID USE IN SEPTIC SHOCK THE ONGOING DEBATE DIEM HO, PHARMD PGY1 PHARMACY RESIDENT VALLEY BAPTIST MEDICAL CENTER BROWNSVILLE 1 ABBREVIATIONS ACCP = American College of Chest Physicians ARF =
More information